Psychiatric Orders in Psychoanalytic Treatment of ASD

NCT05930912 | Unknown FDA Drug

• 2 other identifiers: ASD-Psy-000ASD-000000
• Study Type: observational
• Target: 1
• Locations: 1 country
• Sites: 1

Brief Summary

Autism Spectrum Disorder (ASD) is often accompanied by a variety of other symptoms, such as bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), Social Anxiety Disorder (SAD), Avoidant Personality Disorder (AvPD), Obsessive Compulsive Disorder (OCD), etc. The behavioral and social complications often marginalize the population, impact on life satisfaction, undermined societal values that impact on economic and financial fairness, and so forth. Furthermore, persons with ASD are neurodiverse from standardized pharmacological and clinical cares, and are interpreted disadvantaged in the context of neurotypical treatments. The research protocol aims to differentiate the neuropharmacological implications of ASD from its behavioral and social implications. Such a differentiation is beneficial to the quality of care for neurodiverse population, both in terms of precision treatment in medical settings, and in terms of psychotherapeutic treatment efficacy in the interpretation of behavioral and social traits. The study protocol continues from the adverse event of the participant in NCT05711810 trial, after the positive immunological results in the NCT05839236 trial. The intervention medicine continues from Sertraline adjusted on the choice of Selective Serotonin Reuptake Inhibitor (SSRI) in the previous two trials for complex post-traumatic stress disorder (CPTSD) of the participant, and its combined used with Duloxetine in the choice of Selective Norephedrine Reuptake Inhibitor (SNRI) for norephedrine regulations. The hypothesized target is on the discrete psychiatric intervention centered approach to ASD treatment care. In the PRC where the study is being carried out, amphetamine class medicines are strictly prohibited and defined as illegal substances, regardless of their only proven effect for ASD patient care. Contributed by the sociostructural elements and necessities, black market amphetamine and ketamine have not only emerged in the regime for decades, but also have become a lucrative business. Their recreational uses are also sometimes accompanied by real necessities and needs; black markets cater to the needs but guidance on the usages is based on word-of-mouth stories without professional medical assistances. There is one case the Principal Investigator (PI) collected, that one person, possibly under depression contributed by PTSD, took relatively high dosage of amphetamine and went into a state of psychosis with overwhelming persecution mania. The study protocol, Psychiatric Orders in Psychoanalytic Treatment of ASD, is therefore designed for an evidence-based approach in treating complex psychiatric disorders with psychoanalytic guidance.

Conditions

PTSD; Autism Spectrum Disorder High-Functioning; OCD; Agoraphobia With Panic Attacks; Depression, Unipolar; Depression, Anxiety; Depression and Suicide; Depression, Reactive; Depression; Psychoneurotic; Depression Anxiety Disorder; Panic Disorder With Agoraphobia, Severe Agoraphobic Avoidance and Mild Panic Attacks; Anxiety Disorders; ADHD - Combined Type; Borderline Personality Disorder; Social Anxiety Disorder; Avoidant Personality Disorder; Stockholm Syndrome; Grief; Separation Insecurity

Outcome Measures

Primary Outcomes (12)

• Hamilton Anxiety Rating Scale (HAM-A)

  90 days

• Generalized Anxiety Disorder (GAD-7)

  90 days

• Dissociative Experiences Scale - II (DES-II)

  90 days

• The Defeat Scale (D Scale)

  90 days

• Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

  90 days

• Severity Measure for Agoraphobia-Adult

  90 days

• BPD Check List

  90 days

• Rosenberg Self-Esteem Scale (RSE)

  90 days

• Young Schema Questionnaire (YSQ)

  90 days

• Personality Belief Questionnaire (PBQ)

  90 days

• Behavioral Satisfaction Questionnaire (X axis)

  The X axis score total range -150 to +140, from self-centrism (passive-aggressiveness) to proactive social behaviors.

  90 days

• Behavioral Satisfaction Questionnaire (Y axis)

  The Y axis score total range -200 to +195, from inhibition to excitation of the hypothalamic-pituitary-adrenal (HPA) axis in daily lives.

  90 days

Secondary Outcomes (3)

• Heart Rate

  90 days

• Systolic Blood Pressure

  90 days

• Diastolic Blood Pressure

  90 days

Study Arms (1)

Participant Case

The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.

Diagnostic Test: Psychoanalysis; Drug: sertraline 50mg; Drug: Duloxetine 20 MG; Behavioral: Cognitive Behavioral Therapy

Interventions

Psychoanalysis DIAGNOSTIC_TEST

Case-specific psychoanalysis is performed, including the participant's background during birth.

Also known as: Psychodynamic analysis

Participant Case

sertraline 50mg DRUG

After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.

Also known as: SSRI

Participant Case

Duloxetine 20 MG DRUG

Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.

Also known as: SNRI

Participant Case

Cognitive Behavioral Therapy BEHAVIORAL

CBT is tailored to the participant's current activities and life decisions.

Also known as: CBT

Participant Case

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population is currently Asian, and the sociostructural environment of People's Republic of China is implied.

You may qualify if:

• Persons with ASD.

You may not qualify if:

• Severe ASD cases with central nerve system complications.

Sponsors & Collaborators

• Yang I. Pachankis, PhD: lead
• S for Science: collaborator

Study Sites (1)

Residential Address

Chongqing, Chongqing Municipality, 402762, China

Location

Related Publications (14)

• Yang IP. Questions of COVID-19: Institutional Derogations of Global Health. Lambert Academic Publishing. 2023. ISBN: 978-6206153849.

  BACKGROUND

• Pachankis Y. Jeopardies in human security and politicization of COVID-19. Ethics Med Public Health. 2023 Apr;27:100871. doi: 10.1016/j.jemep.2023.100871. Epub 2023 Feb 1. No abstract available.

  PMID: 36743192 BACKGROUND

• Yang IP. Dictatorial Psychopathological Commination in Server-Side Public Mental & Psychological Menace. Biomedical Science and Clinical Research. 2023; 2(2): 173-184.

  BACKGROUND

• Yang IP. Proton Paths of Cardiac Immune Reflex. Online Journal of Cardiology Research & Reports. 2023; 7(1): 000655.

  BACKGROUND

• Yang IP. What Do We Need in Adolescence?. Journal of Addiction Research. 2023; 7(1): 7-8.

  BACKGROUND

• Yang IP. Proton Decay Reconstruction in Conscious Phenomenon - Literature Review on MRI, EEG, and PET Technologies. Advances in Sexual & Reproductive Health Research. 2022; 1(1): 128-130.

  BACKGROUND

• Yang IP. Correlating Nuclear Sciences to Biochemistry - Mini-review on the Environmental Physiological Impact of Electronic Warfare on Public Health. Journal of Clinical Chemistry. 2022; 1(2): 1-5.

  BACKGROUND

• Yang IP. Mass Surveillance, Behavioural Control, and Psychological Coercion - The Moral Ethical Risks in Commercial Devices. In: Wyld, D. C. & Nagamalai, D. (Eds.) Computer Science and Information Technology. 2022; 151-168. AIRCC Publishing Corporation.

  BACKGROUND

• Yang IP. Technical Analysis on the Cyber Organizational Criminology of Dictatorial Military Conducts -- Experience from Human Trafficking and Coercions by Military Cyber Aggressions. International Journal of Security, Privacy and Trust Management. 2022; 11(3): 1-19.

  BACKGROUND

• Yang IP. The Cultural Revisionist Element behind P. R. China's Neo-Nazism: A Cross-cultural and Cross-religion Research. International Journal of Advanced Multidisciplinary Research and Studies. 2022; 2(4): 435-451.

  BACKGROUND

• Yang IP. A Self--help Guide to Psychoanalysis in Cisgender Homosexual Male. Journal of Marketing Management and Consumer Behavior. 2022; 4(2), 93-110.

  BACKGROUND

• Yang IP. An Evidence-driven Research to the Transgressions of Geneva Conventions by the Communist Party of China Led Autocratic Regime. International Journal of Scientific & Engineering Research. 2022; 13(10): 249-266.

  BACKGROUND

• Yang IP. Targeted Human Trafficking - The Wars between Proxy and Surrogated Economy. International Journal of Scientific & Engineering Research. 2022; 13(7): 398-409.

  BACKGROUND

• Yang IP. Why Should LGBTQI Marriage Be Legalized. Academia Letters. 2022; Article 5157.

  BACKGROUND

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic; Depressive Disorder; Depression; Anxiety Disorders; Suicide; Adjustment Disorders; Borderline Personality Disorder; Phobia, Social; Personality Disorders

Interventions

Sertraline; Duloxetine Hydrochloride; Serotonin and Noradrenaline Reuptake Inhibitors; Cognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

Stress Disorders, Traumatic; Trauma and Stressor Related Disorders; Mental Disorders; Mood Disorders; Behavioral Symptoms; Behavior; Self-Injurious Behavior; Phobic Disorders

Intervention Hierarchy (Ancestors)

1-Naphthylamine; Amines; Organic Chemicals; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Polycyclic Compounds; Thiophenes; Sulfur Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Neurotransmitter Agents; Physiological Effects of Drugs; Behavior Therapy; Psychotherapy; Behavioral Disciplines and Activities

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDIV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: PI

Study Record Dates

• First Submitted: June 11, 2023
• First Posted: July 5, 2023
• Study Start: June 1, 2023
• Primary Completion: September 1, 2023
• Study Completion: December 1, 2023
• Last Updated: July 5, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: The data will be available during the study process, and the archives after completion will stay available.
• Access Criteria: Public.

Locations

CN (1)